APAC Karyotyping Market Market - Industry Trends and Forecast to 2031
The Asia-Pacific karyotyping market is expected to reach USD 69,209.75 thousand by 2030 from USD 40,105.62 thousand in 2022, growing at a CAGR of 7.2% during the forecast period of 2023 to 2030.
Market SegmentationAsia-Pacific Karyotyping Market, By Product (Instruments, Software & Services, and Consumables & Accessories), Type (Spectral Karyotyping, and Virtual Karyotyping), Application (Diagnosis, Personalized Medicines, Research, and Others), End User (Clinical & Research Laboratories, Hospitals, Pathology Laboratories, Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (China, Japan, India, South Korea, Australia, Singapore, Thailand, Indonesia, Philippines, Malaysia, Vietnam, New Zealand, Taiwan, Hong Kong, and Rest of Asia-Pacific) - Industry Trends and Forecast to 2030
Overview of Asia-Pacific Karyotyping Market Dynamics
Drivers
• Rising prevalence of genetic disorders
Restraint
• High cost of karyotyping testing
Opportunity
• Increasing technological advancements and innovation of new medical devices and instruments
Market Players
Some of the major market players operating in the Asia-Pacific karyotyping market are:• Thermo Fisher Scientific Inc.
• Illumina, Inc.
• Agilent Technologies, Inc.
• Sartorius AG
• Abbott
• Leica Biosystems Nussloch GmbH
• CytoTest Inc.
• PerkinElmer Inc.
• BioDot
• Bio-Rad Laboratories, Inc
• Creative Bioarray
• Applied Spectral Imaging
• West Medica Produktions- und Handels- GmbH
• Capricorn Scientific
• Empire Genomics, Inc
• Laboratory Imaging s.r.o.
• SciGene Corporation
• MetaSystems
• MICROPTIC
• Dewinter Optical Inc